Venetoclax is safe and efficacious in relapsed/refractory AML.
Chezi GanzelRon RamAlexander GuralOfir WolachSharon Gino-MoorVladimir VainsteinBoaz NachmiasArie ApelMaya Koren-MichowitzOren PasvolskyRonit YerushalmiIvetta DanyleskoYosef CohenGalit PeretzYakir MosheMiri ZektserShay YeganehJacob M RoweYishai OfranPublished in: Leukemia & lymphoma (2020)
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016-2019, forty patients were identified. Median age was 67 years (21-82), 60% males, median of 2(1-4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- bone marrow
- low dose
- ejection fraction
- newly diagnosed
- acute lymphoblastic leukemia
- chronic kidney disease
- prognostic factors
- high dose
- multiple myeloma
- allogeneic hematopoietic stem cell transplantation
- radiation therapy
- stem cells
- chronic lymphocytic leukemia
- machine learning
- big data
- combination therapy